IAS Benjamin Meaker Visiting Professor: Sean P. David, Stanford University School of Medicine, California, USA

4th September - 1st October 2010

Photo of Dr Sean P. David

Dr David is a Clinical Associate Professor of Family & Community Medicine at Stanford University School of Medicine in Stanford, CA, USA, Research Physician in Translational Medicine at Stanford Research Institute (SRI) International in Menlo Park, CA USA, and Adjunct Associate Professor of Family Medicine at the Warren Alpert Medical School of Brown University.

Dr David earned a Bachelor of Science (B.S.) degree in Zoology (1990) and Medicine (M.D.) (1995) at the University of Washington College of Arts & Sciences and School of Medicine, respectively (Seattle, WA, USA). He subsequently completed a residency in Family Medicine (1995 - 1998) (similar to general practitioner training scheme in UK) at the New Hampshire – Dartmouth Family Medicine Residency Program and Dartmouth Medical School (Concord and Lebanon, NH, USA) where he was Chief Resident, earned a Master of Science (S.M.) in Health & Social Behavior at the Harvard School of Public Health (Boston, MA, USA).

He joined the faculty of the Warren Alpert Medical School of Brown University in 1999 where he founded and directed the Primary Care Genetics Research & Translational Research Center and the C. Everett Koop Health Policy Fellowship. Whilst on the faculty at Brown University, Dr. David completed a Visiting Fellowship in Pharmacogenetics at the Cancer Research UK General Practice Research Group (Radcliffe Infirmary, Oxford, UK) and earned a Doctor of Philosophy (D.Phil.) in Pharmacology at the University of Oxford (1996).

His research encompasses a collaborative, transdisciplinary initiative to translate molecular insights to genomically-tailored and patient-centered personalised medicine. Investigations are focused on the integration of three translational streams of investigation. The first stream triangulates genome-wide association studies with preclinical research using functional neuroimaging and other modalities aimed at elucidating biobehavioural mechanisms nicotine dependence and smoking cessation.

The second stream investigates moderating effects of genotype health-related behaviour and drug response (particularly in smoking cessation treatment) in multiple ancestral populations. The third stream investigates the efficacy of genetically and genomically-tailored drug and behavioural therapies in prospective first-in-human clinical trials, and evidenced-based medicine and policy research (e.g., systematic review/meta-analyses, cost-effectiveness analyses, healthcare delivery systems and educating the primary care workforce).

Dr David will be working with Dr Marcus Munafò, Reader in Biological Psychology, Department of Experimental Psychology, on integrating functional neuroimaging with pharmacogenetic and genomics research and clinical trials aimed at translating molecular insights into personalized medicine in primary care. Their collaboration has been successful in producing scholarship with a high impact on advancing nicotine and tobacco research.

Dr David will present the following lectures as part of his Benjamin Meaker Fast Track Professorship:

1) Faculty Lecture: Biobehavioural mechanisms of bupropion efficacy for smoking cessation, Mon, 13 Sep, 5pm - 6pm, Seminar Room, Department of Experimental Psychology

2) Research Student Lecture: Investigating novel molecular targets for drug response and discovery for smoking cessation - triangulating data from preclinical neuroimaging studies and clinical trials, Wed, 22 Sep, 4pm - 5pm, Lecture Theatre 2, Department of Experimental Psychology

For more information on Dr David's visit, please contact Dr Marcus Munafò.